Nursing and Midwifery Sciences REPLICA S. CAMILLO

The module introduces precision oncology by tracing the transition from histologic classification to molecular profiling, enabling recognition of oncogenic drivers and rationale-based treatment selection. Learners distinguish principles of targeted therapy by comparing small-molecule kinase inhibitors and monoclonal antibodies, then extend this understanding to antibody–drug conjugates as “Trojan horse” platforms with mechanism-linked toxicities and resistance patterns. Immunotherapy is examined along the cancer–immunity cycle, connecting checkpoint blockade to response dynamics, immune-related adverse events, and the role of predictive biomarkers within multidisciplinary management. Tumor-agnostic strategies are framed as approaches guided by actionable alterations irrespective of histology, with attention to evidence generation from basket and umbrella designs and implications for regulation and access. Pharmacology is integrated through analysis of absorption, distribution, metabolism, and excretion, pharmacodynamic targets, polypharmacy, complementary products, and high-risk drug–drug interactions that affect efficacy and safety. Organizational models and enabling technologies are evaluated across outpatient and day-hospital settings, including nurse-navigator programs, digital decision supports, subcutaneous and oral delivery options, and pathways that maintain dose intensity while improving patient experience. Throughout, activities guide participants to recall core concepts, explain mechanisms and biomarkers, apply therapeutic algorithms to realistic cases, analyze genomic and toxicity reports, evaluate risk–benefit in complex comorbid profiles, and design coordinated, patient-centered care plans in collaboration with Molecular Tumor Boards and clinical pharmacists, drawing examples and cases from the provided slides.

Abdel-Wahab, N., et al. (2019). Use of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: A systematic review. *Annals of Internal Medicine*. American Heart Association. (2022). Cardio-oncology drug interactions: A scientific statement from the American Heart Association. *Circulation, 145*(15), e811–e838. Chalmers, Z. R., et al. (2017). Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Medicine*. Chen, D. S., & Mellman, I. (2013). Oncology meets immunology: The cancer–immunity cycle. *Immunity, 39*(1), 1–10. Fruscoloni, G., et al. (2017). Modelli organizzativi per l’erogazione dei trattamenti oncologici: Efficienza e impatto sul paziente. *MECOSAN*. Gazze, G. (2017). Combination therapy for metastatic melanoma: A pharmacist’s role, drug interactions & complementary alternative therapies. *Future Medicine*. Giannakis, M., et al. (2016). Genomic correlates of immune-cell infiltrates in colorectal carcinoma. *Cell Reports, 15*(4), 857–865. Hanahan, D. (2022). Hallmarks of cancer: New dimensions. *Cancer Discovery, 12*(1), 31–46. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. *Cell, 144*(5), 646–674. Johncilla, M., Misdraji, J., Pratt, D. S., Agoston, A. T., Lauwers, G. Y., Srivastava, A., & Doyle, L. A. (2015). Ipilimumab-associated hepatitis: Clinicopathologic characterization in a series of 11 cases. *American Journal of Surgical Pathology, 39*(8), 1075–1084. Larkin, J., et al. (2015). Efficacy and safety in key patient subgroups of nivolumab alone or combined with ipilimumab versus ipilimumab alone in treatment-naïve advanced melanoma (CheckMate 067). *European Journal of Cancer, 51*(Suppl 3), S664–S665. Menzies, A. M., et al. (2021). Neoadjuvant immunotherapy in melanoma: Pathologic response and survival outcomes. *Nature Medicine*. Migden, M. R., et al. (2018). PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. *New England Journal of Medicine, 379*(4), 341–351. Naidoo, J., et al. (2023). Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor–associated immune-related adverse events terminology. *Journal for ImmunoTherapy of Cancer*. Nature Medicine CAPRI trial investigators. (2022). Impact of a nurse-navigator program on treatment delivery for metastatic cancer (CAPRI): Phase 3 randomized trial. *Nature Medicine*. Olofsson, S., et al. (2016). Patient time, costs and preferences for subcutaneous versus intravenous trastuzumab in breast cancer. *The Breast*. Tzanikou, E., & Lianidou, E. (2020). Circulating tumor cells and circulating tumor DNA in liquid biopsy—Recent advances and future perspectives. *Critical Reviews in Clinical Laboratory Sciences, 57*, 54–72. Verschuren, E. C., et al. (2015). Clinical, endoscopic and histologic characteristics of ipilimumab-associated colitis. *Clinical Gastroenterology and Hepatology*. Wan, J. C. M., et al. (2017). Liquid biopsies come of age: Towards implementation of circulating tumour DNA. *Nature Reviews Cancer, 17*, 223–238. Wang, D. Y., Salem, J., Cohen, J. V., et al. (2018). Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. *JAMA Oncology, 4*(12), 1721–1728*.